Monday 20 July 2026

One To Watch

Invivyd

A commercial-stage company developing antibody-based therapies for viruses, beginning with SARS-CoV-2.

Company Overview

Want to Update your Company's Profile?


Latest Invivyd News

FDA revises EUA on COVID-19 treatment Pemgarda
27 August 2024
FDA grants EUA to Invivyd’s Pemgarda for PrEP of COVID-19
25 March 2024
More Invivyd news >


Today's issue

FDA accepts Shionogi’s sNDA for Fetroja
Pharmaceutical
FDA accepts Shionogi’s sNDA for Fetroja
20 July 2026
Pharmaceutical
BMS expands NVIDIA tie-up with Vera Rubin AI factory
20 July 2026
Pharmaceutical
Gates Medical Research Institute links up with SII on vaccines
20 July 2026
Biotechnology
Almirall seeks broader EU approval for Ebglyss in younger children with atopic dermatitis
20 July 2026
Biotechnology
Regenxbio prices expected $100M public offering
20 July 2026
Pharmaceutical
From persistence to precision: how Daiichi Sankyo is evolving its R&D strategy in oncology
20 July 2026
Biotechnology
4DMT reports two-year benefit for wet AMD gene therapy
20 July 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze